BCWORLD PHARM (200780) Fundamentals 2026 — Revenue Analysis | SniperIQ
BCWORLD PHARM (200780) is a KR-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₩32.3B, trading at ₩3160.00 on the KOE. This SniperIQ fundamentals page covers BCWORLD PHARM's valuation, profitability (net margin -3.1%), revenue (₩75.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BCWORLD PHARM's market cap?
BCWORLD PHARM (200780) has a market capitalization of approximately ₩32.3B, trading at ₩3160.00 on the KOE. Market cap moves with the live share price.
What is BCWORLD PHARM's P/E ratio?
BCWORLD PHARM's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is BCWORLD PHARM?
BCWORLD PHARM runs a net profit margin of -3.1%, a gross margin of 38.3%, and an operating margin of 5.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does BCWORLD PHARM generate?
BCWORLD PHARM reported revenue of ₩75.8B for fiscal year 2025, with net income of -₩4.9B and earnings per share (EPS) of -527.02. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does BCWORLD PHARM pay a dividend?
BCWORLD PHARM offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is BCWORLD PHARM financially healthy?
BCWORLD PHARM carries a debt-to-equity ratio of 1.24x and a current ratio of 0.56x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is BCWORLD PHARM a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BCWORLD PHARM (200780) the key facts are: market cap ₩32.3B, revenue ₩75.8B, 52-week range 2890-6030. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track BCWORLD PHARM's full fundamentals live
Get BCWORLD PHARM's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.